Skip to main content

Table 1 Patients with no known neurological disease

From: Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis

# Diagnosis Sex Age at Death (yr) PMI (hr) Brain weight (g) ALS stage Braak stage Thal phase CERAD LBD
1 normal M 47 12 1383 0 I/II 0 0 no
2 normal M 70 10.5 1388 0 I/II 1 0 no
3 normal F 72 7 1406 0 I/II 0 0 no
4 normal F 65 19 1207 0 0 1 0 no
5 normal F 56 12 1416 0 I/II n/a 0 no
6 normal M 61 6 1369 0 0 1 0 no
7 normal M 55 11.5 1448 0 0 n/a 0 no
8 normal F 59 13 1166 0 0 n/a 0 no
9 normal M 68 21 1330 0 I/II 0 0 no
10 normal M 47 11 1333 0 I/II n/a A no
11 normal M 72 13.5 1320 0 I/II 3 A no
12 normal F 46 12 1228 0 0 n/a 0 no
13 normal F 65 22 1206 0 I/II 1 0 no
14 normal M 67 15 1545 0 I/II 2 A no
15 normal F 68 15 1151 0 I/II 0 0 no
16 normal M 70 36 1755 0 0 0 0 no
  1. Abbreviations: #: case number, Normal diagnosed neurologically normal, F female, M male, PMI postmortem interval, ALS stage stages 0–4 semiquantitatively assessed according to [14, 15]. Braak stage neurofibrillary tangle deposition according to [12, 13]. Thal phase amyloid deposition according to [108]. CERAD neuritic plaque deposition according to [76, 80]. LBD Lewy Body disease according to [75]. n/a data not available. no no LBD